Gilead’s Remdesivir Receives the US FDA’s Emergency Use Authorization for the Treatment of COVID-19

Shots:

• The EUA is based on two global P-III studies assessing 5-day & 10-day dosing durations of remdesivir (IV) vs PBO in patients with mod. to sev. symptoms of COVID-19, including those who are critically ill. Multiple additional clinical studies are ongoing to evaluate the safety and efficacy of remdesivir as a treatment for COVID-19
• Under EUA, the 10-day & 5-day dosing regimen is for the patients requiring & not requiring invasive mechanical ventilation and/or ECMO respectively. If a patient on the 5-day dosing regimen does not demonstrate clinical improvement after 5days, treatment may extend for up to 5 additional days
• The EUA will expedite broader use of remdesivir to treat hospitalized patients with severe COVID-19, enabling access to remdesivir at additional hospitals across the US

Click here ­to­ read full press release/ article | Ref: Gilead | Image: Gilead

Related News:   Gilead Reports Results of Remdesivir in P-III SIMPLE Studies for Patients with Severe COVID-19